The impact of COVID-19 on the healthcare industry and policy decisions

episode

The Decisive Podcast: Insights and analysis to empower confident decision-making. not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from The Decisive Podcast: Insights and analysis to empower confident decision-making.

Beyond Disruption: The Next Chapter for GCC Economies 33 min · 15 Aug 2026

PMI in Focus: High Frequency Signals for an Uncertain Business Environment 18 min · 18 Jul 2026

Frequently Asked Questions: Oil Shocks, Economic Resilience and Risks to Growth 21 min · 11 Jul 2026

The Age of Agility: Midyear Signals for 2026 - Part 2 18 min · 04 Jul 2026

The Age of Agility: Midyear Signals for 2026 30 min · 27 Jun 2026

Uneven Demand, Tight Supply: Navigating the Next Procurement Challenge 28 min · 20 Jun 2026

All episodes from The Decisive Podcast: Insights and analysis to empower confident decision-making. →

Report any issue

Source

Recorded11 Jun 2020

Publisherfeeds.libsyn.com ↗

Handlerec:6370400

Show notes

As countries and organizations start to reopen, the question top-of-mind for many is when will a vaccine, or other treatment, be available? Many hold out hope that a vaccine will be the magic bullet — it's not that simple. Our life science's experts Gustav Ando and Milena Izmirlieva spend todays' episode discussing the challenges and opportunities for developing a vaccine as well as the alternative therapies that are being tested in tandem to alleviate many of the symptoms of COVID-19. How has the industry risen to the challenge and what does this mean for future R&D? Gustav Ando, Vice President, Industry Services & Life Sciences, IHS Markit https://ihsmarkit.com/experts/ando-gustav.html Milena Izmirlieva, Director, Life Sciences, IHS Markit https://ihsmarkit.com/experts/izmirlieva-milena.html

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in